Understanding how some HER2 positive breast cancer cells survive treatment
Molecular ontology of drug tolerant persisters in HER2 positive breast cancer - Resubmission - 1
This study is looking at why some HER2 positive breast cancer cells can survive treatment and how they go into a resting state, which might help us find better ways to stop these cells from resisting therapy and improve outcomes for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11002660 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind drug-tolerant persisters (DTPs) in HER2 positive breast cancer, which are cells that survive despite treatment with targeted therapies. The study focuses on how these cells enter a dormant state and the genetic factors that contribute to their resilience against therapies like tyrosine kinase inhibitors. By analyzing patient samples and cancer cell lines, the research aims to identify the characteristics of these DTPs and their role in treatment resistance. This could lead to new strategies to prevent resistance and improve treatment outcomes for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with HER2 positive breast cancer who are undergoing treatment with tyrosine kinase inhibitors.
Not a fit: Patients with other types of breast cancer or those who are not receiving targeted therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for HER2 positive breast cancer, potentially converting temporary remissions into long-term cures.
How similar studies have performed: Previous research has shown success in understanding drug resistance mechanisms in other cancers, suggesting that this approach may yield valuable insights for HER2 positive breast cancer as well.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Skok, Jane Amanda — New York University School of Medicine
- Study coordinator: Skok, Jane Amanda
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.